Antibody Contract Manufacturing Market, 2020-2030 - Roots Analysis

Roots Analysis has announced the addition of the "Antibody Contract Manufacturing Market, 2020-2030" report to its list of offerings.
AMSTERDAM, N.Y. - Nov. 26, 2020 - PRLog -- To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this link

Key Market Insights

Over 100 CMOs presently claim to offer manufacturing services for antibodies

The antibody contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial).

More than 90% service providers are focused on the production of monoclonal antibodies

However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments.

Europe has emerged as a key manufacturing hub for antibody-based products

More than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe. Additionally, 40% of the total installed capacity is in Europe, followed by Asia. Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan.

More than 90 partnership agreements have been inked between 2013 and 2019

Multiple expansion initiatives were undertaken by CMOs between 2017 and 2019

More than 50% of such initiatives were reported to be focused on the expansion of manufacturing facilities, followed by building new facilities (38%). It is worth noting that close to 50% of the total number of expansion initiatives were undertaken in Europe, of which, 25% were in the UK.

Demand for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during 2020-2025

Given the fact that there are a number of antibody-based products in the market, the commercial demand for antibodies is significantly higher than the clinical demand. Across the three major global regions, North America represent over half of the overall global manufacturing demand for antibodies.

North America and Europe are anticipated to capture over 70% of the market share by 2030

To request a sample copy / brochure of this report, please visit this link (

For additional details, please visit or email

You may also be interested in the following titles:

1.     Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 (

2.     Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030 (

3.     Antibody Drug Conjugates Market (5th Edition), 2019-2030 (


Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Roots Analysis
Email:*** Email Verified
Location:Amsterdam - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Roots Analysis News
Most Viewed
Daily News

Like PRLog?
Click to Share